An extended-release version of deucrictibant reduced patients’ mean monthly attack rate by 83% compared to placebo, meeting the primary endpoint in a Phase 3 trial.
Pharvaris claims it achieved “injectable-like efficacy” in a once-daily pill for a debilitating genetic disease.
The experimental drug, an extended-release version of deucrictibant, is designed …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
The FDA agreed to review the company's treatment for a swelling disease.
As Regeneron’s cancer portfolio continues to suffer setbacks, the company is placing a bet in a different direction through a…
FDA delays Capricor's deramiocel decision to Nov. 22, reviewing new HOPE-3 data for narrower upper limb indication in Duchenne…
Deucravacitinib demonstrated “superior efficacy” and tolerability vs. placebo at 16 weeks, and sustained efficacy through 52…
Capricor Therapeutics shares surged significantly after the FDA agreed to review new drug data. The company had faced setbacks…
Parabilis Medicines, the decade-old and well-funded
